ASCO 2023 | OniLon: trifluridine/tipiracil with nanoliposomal irinotecan in advanced CRC

Olatunji Alese, MD, Emory Winship Cancer Institute, Atlanta, GA, describes the trial design of the Phase II OniLon trial (NCT03368963) of trifluridine/tipiracil (TAS-102) with nanoliposomal irinotecan (nal-IRI) in patients with advanced or metastatic colorectal cancer (CRC). Patients in this single arm trial were pre-treated with one prior line of therapy, where half of patients have previously received bevacizumab. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.